There could be some big returns on offer in the healthcare sector for Australian investors according to analysts.
For example, the three ASX 200 healthcare stocks listed below have all been named as buys by analysts and tipped to deliver double-digits from current levels.
Here's what they are saying about them:
CSL Ltd (ASX: CSL)
The first ASX 200 healthcare stock that could be a buy is CSL. It is the biotechnology giant behind the CSL Behring plasma therapies business, the CSL Seqirus vaccines business, and the CSL Vifor iron deficiency and nephrology business.
Macquarie is feeling very bullish about the company due to the positive medium-term outlook for CSL Behring's immunoglobulins. As a result, earlier this week, it upgraded the company's shares to an outperform rating with an improved price target of $330.00. This implies a potential upside of 17% for investors over the next 12 months.
But its shares may not stop there. It is also worth noting that Macquarie sees scope for CSL's shares to rise beyond $500 within three years.
ResMed Inc. (ASX: RMD)
Over at Morgans, its analysts think that ResMed would be a great option for investors looking for healthcare exposure. ResMed is the global leader in sleep disorder treatment solutions.
This is a great area of the market to be in given the huge addressable market. It has previously been estimated that 1 in 5 people suffer from sleep apnoea. However, the vast majority of these sufferers are undiagnosed. This gives ResMed a huge growth runway even with the emergence of weight loss wonder drugs.
In fact, Morgans' analysts recently stated that they "see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers."
Morgans has an add rating and a $32.82 price target on its shares. This suggests a potential upside of 13% for investors.
Telix Pharmaceuticals Ltd (ASX: TLX)
Finally, the team at Bell Potter think that Telix could be an ASX 200 healthcare stock to buy. It is the radiopharmaceutical company behind the increasingly popular Illuccix prostate cancer imaging agent.
Its analysts believe Telix is well-positioned for growth over the coming years and are forecasting revenue increasing from $502.5 million in FY 2023 to $993.7 million in FY 2026. The broker is also expecting its EBITDA to grow at an even quicker rate. It has pencilled in EBITDA of $211.1 million in FY 2026, which compares favourably to FY 2023's EBITDA of $58.4 million.
This morning, the broker reiterated its buy rating and $14.50 price target on the company's shares. This implies a potential upside of approximately 13% from where its shares trade today.
